Page 57 - Biomarkers for risk stratification and guidance in heart failure
P. 57
Chapter 3
Table 3. Response to elevated NT-proBNP levels in the NT-proBNP-guided group during follow-up.
Type of intervention
Drug intervention* Diuretics
ACE-I’s
Beta-blockers
Digoxin
Aldosterone antagonists ARBs
Nitrates
Alpha-blocker
Anti-arrhythmic
Hydralazine
Decrease calcium-channel blocker Diagnostics
Echocardiogram Ischemia†
Holter monitoring Consultation‡ Chest X-ray
Other interventions Admission HF
ED visit
Pacemaker implantation ICD implantation Admission other Rehabilitation for HF Analysis/treatment anemia Life style advice
Electro cardioversion No intervention
No treatment options On dialysis
Severe hypotension
No valid reason
No NT-proBNP at disposal
Intervention refused by patient
Total number visits with elevated NT-proBNP
N (%)
202(75.1)
109(40.5) 17(6.3) 30(11.2) 9(3.3) 11(4.1) 11(4.1) 10(3.7) 1(0.4) 1(0.4) 1(0.4) 2(0.7) 28(10.4) 8(3.0) 6(2.2) 7(2.6) 5(1.9) 2(0.7) 34(12.6) 18(6.7) 1(0.4) 1(0.4) 2(0.7) 2(0.7) 1(0.4) 3(1.1) 2(0.7) 4(1.5) 56(20.8) 5(1.9) 2(0.7) 1(0.4) 46(17.1) 1(0.4) 1(0.4) 269 (100)
*Except for calcium-channel blockers, drug intervention indicates start, increase or switch in medication. †MIBI stress test, coronary angiography, or exercise test. ‡Specialized cardiologist/internal medicine/ other. ACE-I=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; NT-proBNP=N- terminal pro–B-type natriuretic peptide.
56
